Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 28.20
NVIV's Cash to Debt is ranked lower than
52% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. NVIV: 28.20 )
Ranked among companies with meaningful Cash to Debt only.
NVIV' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 29.08 Max: No Debt
Current: 28.2
F-Score: 4
Z-Score: 19.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -73.39
NVIV's ROE (%) is ranked lower than
73% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NVIV: -73.39 )
Ranked among companies with meaningful ROE (%) only.
NVIV' s ROE (%) Range Over the Past 10 Years
Min: -775.86  Med: -360 Max: -30.97
Current: -73.39
-775.86
-30.97
ROA (%) -57.38
NVIV's ROA (%) is ranked lower than
74% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. NVIV: -57.38 )
Ranked among companies with meaningful ROA (%) only.
NVIV' s ROA (%) Range Over the Past 10 Years
Min: -1218.1  Med: -250.22 Max: 42.86
Current: -57.38
-1218.1
42.86
ROC (Joel Greenblatt) (%) -1913.11
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. NVIV: -1913.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVIV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3330.38  Med: -1292.8 Max: 334.39
Current: -1913.11
-3330.38
334.39
EBITDA Growth (3Y)(%) 6.40
NVIV's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. NVIV: 6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVIV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.2  Med: 6.4 Max: 367.8
Current: 6.4
-62.2
367.8
EPS Growth (3Y)(%) -32.30
NVIV's EPS Growth (3Y)(%) is ranked lower than
82% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NVIV: -32.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVIV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -32.3 Max: 274.4
Current: -32.3
0
274.4
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

NVIV Guru Trades in

NVIV Guru Trades in

Q1 2016

NVIV Guru Trades in Q1 2016

Jim Simons 31,700 sh (New)
» More
Q2 2016

NVIV Guru Trades in Q2 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:IDRA, NAS:CYAD, NAS:MNOV, NAS:CYNA, NAS:CNCE, NAS:ESPR, NAS:RXDX, NAS:VTAE, NAS:CRIS, NAS:CCXI, NAS:EDGE, NAS:OVAS, NAS:AGTC, AMEX:MDGN, NAS:BSTC, NAS:IMGN, NAS:FOMX, OTCPK:SPHRY, NAS:FLKS, NAS:ABUS » details
Traded in other countries:04IA.Germany,
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.

InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.

Ratios

vs
industry
vs
history
P/B 6.05
NVIV's P/B is ranked lower than
70% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. NVIV: 6.05 )
Ranked among companies with meaningful P/B only.
NVIV' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 67.4
Current: 6.05
0
67.4
Current Ratio 9.23
NVIV's Current Ratio is ranked higher than
75% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. NVIV: 9.23 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 2.09 Max: 14.81
Current: 9.23
0.14
14.81
Quick Ratio 9.23
NVIV's Quick Ratio is ranked higher than
75% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. NVIV: 9.23 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 2.09 Max: 14.81
Current: 9.23
0.14
14.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.40
NVIV's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. NVIV: -20.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVIV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -121  Med: -74.5 Max: -20.4
Current: -20.4
-121
-20.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.54
NVIV's Price/Net Cash is ranked lower than
54% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. NVIV: 6.54 )
Ranked among companies with meaningful Price/Net Cash only.
NVIV' s Price/Net Cash Range Over the Past 10 Years
Min: 4.72  Med: 16.3 Max: 48
Current: 6.54
4.72
48
Price/Net Current Asset Value 6.37
NVIV's Price/Net Current Asset Value is ranked lower than
57% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. NVIV: 6.37 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVIV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.44  Med: 15.57 Max: 34.94
Current: 6.37
4.44
34.94
Price/Tangible Book 6.20
NVIV's Price/Tangible Book is ranked lower than
63% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. NVIV: 6.20 )
Ranked among companies with meaningful Price/Tangible Book only.
NVIV' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.83  Med: 13.92 Max: 29.63
Current: 6.2
3.83
29.63
Earnings Yield (Greenblatt) (%) -9.89
NVIV's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. NVIV: -9.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVIV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -45.99  Med: 0 Max: 1000
Current: -9.89
-45.99
1000

More Statistics

EPS (TTM) $ -0.66
Beta3.55
Short Percentage of Float9.35%
52-Week Range $3.50 - 11.80
Shares Outstanding (Mil)31.93

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.08 -1.16 -0.89
EPS w/o NRI ($) -1.08 -1.16 -0.89
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
NVIV: 5th Patient Conversion Supports Target Price Increase Aug 23 2016
These 7 Stocks Under $10 Could Make You a Lot of Money Aug 19 2016
Vonage Is Starting to Look Technically Attractive Aug 18 2016
InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study Aug 18 2016
InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study Aug 18 2016
InVivo Therapeutics Announces Fifth Patient Conversion in INSPIRE Study of the Neuro-Spinal... Aug 17 2016
InVivo Therapeutics Announces Fifth Patient Conversion in INSPIRE Study of the Neuro-Spinal... Aug 17 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Aug 12 2016
InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer Aug 11 2016
InVivo Therapeutics Appoints Pamela Stahl as Chief Commercial Officer Aug 11 2016
NVIV: New Sites Announced, Trial Expansion Approved, Enrollees Needed. Aug 09 2016
InVivo reports 2Q loss Aug 05 2016
InVivo reports 2Q loss Aug 05 2016
InVivo Therapeutics Reports 2016 Second Quarter Financial Results and Business Update Aug 04 2016
InVivo Therapeutics Reports 2016 Second Quarter Financial Results and Business Update Aug 04 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-Q, Quarterly Report Aug 04 2016
Coverage initiated on InVivo Therapeutics by Ladenburg Thalmann Jul 21 2016
InVivo Therapeutics Announces Ben Taub Hospital/Baylor College of Medicine as New Site for INSPIRE... Jul 18 2016
InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study Jul 14 2016
InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study Jul 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)